Celltrion Inc

Price Chart

Risk-Adjusted Performance

Celltrion Inc (068270) Price Performance

Celltrion Inc (068270) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW207500.00, down 0.72% from the previous close.

Over the past year, 068270 has traded between a low of KRW145353.36 and a high of KRW248500.00. The stock has gained 37.5% over this period. It is currently 16.5% below its 52-week high.

Celltrion Inc has a market capitalization of $45.40T, with a price-to-earnings ratio of 44.09 and a dividend yield of 0.37%.

About Celltrion Inc

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.